On the other hand, the difference between patients with pancreatic cancer with low and high RRM1 expression in the GEM group did not reach statistical significance, though there was a trend towards better survival treating with gemcitabine (S4B Fig). This evidence concerns the gene RRM1 and pancreatic neoplasm.